- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Special Cases
Session Date/Time: Monday 07/10/2013 | 17:00-18:30
Paper Time: 17:48
Venue: Elicium 1 (First Floor)
First Author: : A.Karalezli TURKEY
Co Author(s): : B. Ekinci Koktekir G. Celik C. Kucukerdonmez
To investigate the acute effects of topiramate on anterior chamber angle and choroidal thickness in migraine patients.
This prospective study included 15 eyes of 15 migraine patients in whom topiramate therapy was started. All of the patients underwent complete ophthalmic examination including measurement of anterior chamber angle (ACA) and choroidal thickness (CT) by a FD-OCT device (Optovue Inc., Fremont, CA), at the baseline and at the first week of therapy. The patients were asked to report if they have any pain or discomfort in the eye after the initiation of topiramate therapy at the second visit. The statistical evaluation was performed by Wilcoxon test (SPSS 16.0 Inc) and a p value lower than 0.05 was accepted as statistically significant.
None of the patients experienced pain or discomfort. The mean baseline anterior chamber angle significantly decreased from 40.34±7.06° to 36.89±6.87° at the first week of therapy (p=0.001). The mean baseline choroidal thickness increased from 277.33±95.60µ to to 323.40±84.50µ at the first week of the topiramate therapy, which was also statistically significant (p=0.01).
Topiramate can acutely decrease the anterior chamber angle and increase the choroidal thickness. As these effects may be asymptomatic, migraine patients who started this therapy should be warned to be closely followed up by an ophthalmologist.
Please wait while information is loading.